Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 3Genitourinary 2Breast 2Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 3Prostatic Neoplasms 1Peripheral Nervous System Diseases 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × sagopilone × Gynecologic × Clear all
NCT00325351 2021-04-08

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Bayer

Phase 2 Completed
45 enrolled
Gynecologic

Ovarian Neoplasms

NCT00246688 2015-12-31

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Bayer

Phase 2 Completed
63 enrolled
Gynecologic

Ovarian Neoplasms

NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡